
Senti Biosciences Investor Relations Material
Latest events

Status Update
Senti Biosciences

Corporate Presentation
8 Sep, 2025

Q2 2025
7 Aug, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Senti Biosciences Inc
Access all reports
Senti Biosciences Inc. is a biotechnology company engaged in developing innovative cell and gene therapies. The company specializes in the use of gene circuit technologies, which involve designing and programming cells to function as intelligent medicines capable of addressing various diseases. Senti Biosciences’ platform focuses on three main areas: off-the-shelf CAR-NK cells for oncology, gene therapies targeting specific tissues, and cell therapies for regenerative medicine. Their lead product candidates include therapies targeting different types of cancer using CAR-NK cells engineered with these gene circuits. Senti Biosciences is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
SNTI
Country
🇺🇸 United States